Buckingham Asset Management LLC Has $1.39 Million Stake in Merck & Co. (MRK)

Buckingham Asset Management LLC lifted its position in Merck & Co. (NYSE:MRK) by 26.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,681 shares of the company’s stock after buying an additional 5,118 shares during the period. Buckingham Asset Management LLC’s holdings in Merck & Co. were worth $1,389,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. American International Group Inc. lifted its stake in shares of Merck & Co. by 992.8% in the fourth quarter. American International Group Inc. now owns 9,152,305 shares of the company’s stock worth $515,000,000 after buying an additional 8,314,765 shares in the last quarter. Janus Henderson Group PLC lifted its position in Merck & Co. by 172.3% during the third quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock valued at $429,347,000 after purchasing an additional 4,243,246 shares during the period. Capital International Investors lifted its position in Merck & Co. by 55.3% during the third quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock valued at $616,185,000 after purchasing an additional 3,428,400 shares during the period. Vanguard Group Inc. lifted its position in Merck & Co. by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after purchasing an additional 3,312,459 shares during the period. Finally, Stifel Financial Corp lifted its position in Merck & Co. by 95,700.4% during the third quarter. Stifel Financial Corp now owns 3,281,163 shares of the company’s stock valued at $210,016,000 after purchasing an additional 3,277,738 shares during the period. Hedge funds and other institutional investors own 74.62% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NYSE MRK opened at $60.09 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06. The firm has a market capitalization of $158,616.86, a PE ratio of 15.10, a PEG ratio of 2.44 and a beta of 0.77. Merck & Co. has a 1 year low of $52.83 and a 1 year high of $66.41.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The firm had revenue of $10.43 billion during the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.89 earnings per share. research analysts predict that Merck & Co. will post 4.17 earnings per share for the current fiscal year.

MRK has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research report on Tuesday, April 17th. ValuEngine upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Morgan Stanley upgraded shares of Merck & Co. from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $59.80 to $63.00 in a research report on Tuesday, April 17th. Barclays upgraded shares of Merck & Co. from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $62.00 to $64.00 in a research report on Thursday, April 5th. Finally, SunTrust Banks upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating and increased their price objective for the company from $54.00 to $72.00 in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. Merck & Co. has an average rating of “Buy” and an average target price of $65.82.

In other news, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the sale, the director now directly owns 5,100 shares of the company’s stock, valued at $273,207. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total transaction of $1,392,000.00. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/25/buckingham-asset-management-llc-has-1-39-million-stake-in-merck-co-mrk.html.

Merck & Co. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply